Chapter

Theranostics and Translation toward Personalized Medicine for Multiple Sclerosis

Ariel Miller, Tamar Paperna, Opher Caspi, Izabella Lejbkowicz, Elsebeth Staun-Ram and Nili Avidan

in Integrative Neuroscience and Personalized Medicine

Published in print December 2010 | ISBN: 9780195393804
Published online January 2011 | e-ISBN: 9780199863495 | DOI: http://dx.doi.org/10.1093/acprof:oso/9780195393804.003.0011
Theranostics and Translation toward Personalized Medicine for Multiple Sclerosis

Show Summary Details

Preview

Recently, medicine began moving to more informed healthcare management and medical treatment guided by diagnostics, termed, theranostics. In the last decade, the search for markers for disease subtypes and more personalized treatment responses has been accelerated by academic researchers and pharmaceutical companies. Currently used high-throughput genome-wide methodology is resulting in a shift to a hypothesis-free approach to identify appropriate genes. This, in turn, has resulted in the identification of a multitude of biomarker candidates that explain a small fraction of patients’ variations in drug response therapy or disease clinical course. These research initiatives need to be followed by functional studies to determine the molecular mode of action and clinical utility of these markers. Here, the status of identification of biomarkers for diagnosis, disease course, treatment response, and related factors involved in development and response to treatment for multiple sclerosis are reviewed.

Keywords: Multiple sclerosis; biomarkers; pharmacogenetics; theranostics; interferon beta; GWAS; microarray

Chapter.  23478 words. 

Subjects: Neuroscience

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.